Nektar Therapeutics Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Nektar Therapeutics (NKTR) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $459.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-03-13
- Nektar Therapeutics unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $459.00K, a 32.30% decline from fiscal 2024.
- Nektar Therapeutics unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $678.00K, a 147.45% increase from fiscal 2023.
- Nektar Therapeutics unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $274.00K, a 33.01% decline from fiscal 2022.
- Nektar Therapeutics unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $409.00K.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|
| 2025-12-31 | $459.00K 10-K · filed 2026-03-13 |
| 2024-12-31 | $678.00K 10-K · filed 2026-03-13 |
| 2023-12-31 | $274.00K 10-K · filed 2025-03-14 |
| 2022-12-31 | $409.00K 10-K · filed 2024-03-05 |
| 2021-12-31 | $0.00 10-K · filed 2024-03-05 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-28 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-01 |
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 |
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 |
| 2012-12-31 | $137.00K 10-K · filed 2015-02-26 |
| 2011-12-31 | $0.00 10-K · filed 2012-02-29 |
| 2010-12-31 | $0.00 10-K · filed 2012-02-29 |
| 2009-12-31 | $0.00 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |